NeuroSense Therapeutics Ltd. Stock price

Equities

NRSN

IL0011809592

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.82 USD +5.20% Intraday chart for NeuroSense Therapeutics Ltd. +0.55% +131.85%
Sales 2023 * - Sales 2024 * - Capitalization 24.87M
Net income 2023 * -11M Net income 2024 * -14M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-2.22 x
P/E ratio 2024 *
-2.21 x
Employees 14
Yield 2023 *
-
Yield 2024 *
-
Free-Float 67.34%
More Fundamentals * Assessed data
Dynamic Chart
Neurosense Therapeutics Ltd. Reports Additional Positive Results from Its ALS Phase 2B Paradigm Trial CI
NeuroSense Gets Non-Compliance Notice From Nasdaq MT
Neurosense Therapeutics Ltd. Reports Additional Positive Efficacy Data from Further Evaluation of Its Phase 2B Als Trial CI
NeuroSense Therapeutics Ltd.'s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints CI
Top Premarket Gainers MT
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Neurosense Receives U.S. Fda Confirmation of Cmc Strategy for Primec in Preparation for Pivotal Phase 3 in Als and Commercial Readiness CI
NeuroSense Therapeutics Ltd. Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023 CI
Neurosense Therapeutics Ltd. Announces Results of Non-Sponsored in Vitro Study of PrimeC in Amyotrophic Lateral Sclerosis CI
Neurosense Therapeucs Ltd. Opens an Eu Office CI
European Medicines Agency Grants the Small and Medium-Sized Enterprise Status of Neurosense Therapeutics Ltd CI
European Medicines Agency Grants Neurosense SME Status CI
NeuroSense Secures Patents in Europe, Japan, Israel for ALS Drug Candidate; Shares Rise MT
NeuroSense Therapeutics Ltd. Receives Patents in Europe, Japan, and Israel for its ALS Drug PrimeC CI
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news
1 day+5.20%
1 week+0.55%
Current month+2.82%
1 month+1.11%
3 months+133.33%
6 months+142.67%
Current year+131.85%
More quotes
1 week
1.45
Extreme 1.45
1.85
1 month
1.31
Extreme 1.31
2.33
Current year
0.76
Extreme 0.761
2.33
1 year
0.40
Extreme 0.4
2.33
3 years
0.40
Extreme 0.4
8.18
5 years
0.40
Extreme 0.4
8.18
10 years
0.40
Extreme 0.4
8.18
More quotes
Managers TitleAgeSince
Founder 45 17-02-12
Director of Finance/CFO 42 21-05-31
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 56 21-12-20
Chairman 67 21-09-30
Director/Board Member 64 21-11-30
More insiders
Date Price Change Volume
24-03-28 1.82 +5.20% 113,890
24-03-27 1.73 +1.76% 82,381
24-03-26 1.7 -6.59% 133,816
24-03-25 1.82 +3.41% 56,461
24-03-22 1.76 -2.76% 184,142

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.82 USD
Average target price
5.25 USD
Spread / Average Target
+188.46%
Consensus
  1. Stock
  2. Equities
  3. Stock NeuroSense Therapeutics Ltd. - Nasdaq